GSK2857916 Demonstrates 60% Response Rate in Heavily Pre-treated Relapsed/Refractory Multiple Myeloma Patients
Published on 12th December
The investigational BCMA antibody-drug conjugate GSK2857916, also known as J6M0-mcMMAF, recently awarded Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and PRIME designation from the European Medicines Agency (EMA), shows a positive response in a group of hard to treat and heavily pre-treated relapsed/refractory multiple myeloma patients.
The results came from the dose expansion phase of the Phase I/II DREAMM-1 study.
GSK2857916 is an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate. The drug comprises a humanised anti- B cell maturation antigen (BCMA) monoclonal antibody conjugated to the cytotoxic agent monomethyl auristatin F via non-cleavable linker.
The drug linker technology in GSK2857916 is licensed from Seattle Genetics. The monoclonal antibody is produced using Potelligent® Technology licensed from BioWa. The technology eliminates fucose from sugar chains on an antibody, thereby enhancing Antibody Dependent Cellular Cytotoxicity (ADCC), the critical factor in anti-tumor activity.
GSK2857916 monotherapy demonstrated a 60% response rate and a median progression free survival of 7.9 months
The results of the DREAMM-1 study were presented by Suzanne Trudel, MD, FRCP(C), Associate Professor, Ontario Cancer Institute/Princess Margaret Hospital, Toronto, Ontario (Canada), during an oral presentation at the 59th annual meeting of the American Society for Hematology (ASH) held December 9 – 12, 2017 in Atlanta, GA (USA).
B-cell maturation antigens are cell surface receptors in the TNF superfamily with expression restricted to B lineage cells at later stages of differentiation, which is required for the survival of long lived plasma cells. The normal function of BCMA is to promote plasma cell survival by transduction of signals from two known ligands, BAFF and APRIL. However, this pathway has also been shown to be important for myeloma cell growth and survival. BCMA is expressed at varying levels in myeloma patients and BCMA membrane expression is universally detected in myeloma cell lines.
The DREAM-1 study is an open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics, immunogenicity and clinical activity of the antibody drug conjugate GSK2857916 in subjects with relapsed/refractory multiple myeloma and other advanced hematologic malignancies expressing BCMA.
The study consists of two parts. The first part includes a dose escalation phase while the second part of the study is an expansion phase for safety, tolerability, PK, PD, and clinical activity testing.
Overall, the study is expected enroll a total of approximately 80-95 subjects with relapsed/refractory MM or BCMA-expressing hematologic malignancies. The maximum dose to be administered in this trial will not exceed 5 mg/kg.
Patients were enrolled in the DREAMM-1 study independent of BCMA expression levels. The study participants (n=35) were heavily pre-treated, with 57% of the patients having at least five prior lines of treatment and 40% having prior daratumumab treatment.
The results presented at this years ASH annual meeting demonstrates that GSK2857916 monotherapy offers a 60% response rate (95% confidence interval [CI]: 42.1% – 76.1%) and a median progression free survival of 7.9 months (95% CI: 3.1 – not estimable).
Overall, the results show a manageable safety profile, with thrombocytopenia/ platelet count (57%) decreased and low grade corneal events (63%) being the most frequently reported Adverse Events and also the most frequent reason for dose modifications.*
The study results did not show dose-limiting toxicities.
Infusion-related reactions (IRRs) occurred in 23% of patients (without pre-medication) on the first infusion and no IRRs occurred on subsequent infusions.
“The patients participating in the DREAMM-1 trial had very limited options for further treatment, so we are encouraged by the response rate seen in this trial,” Axel Hoos, Senior Vice President Oncology Research & Development at GSK, noted.
“GSK2857916 is the leading asset in our emerging pipeline of potentially transformative Oncology medicines and we plan to rapidly progress its development programme, initiating pivotal monotherapy studies as well as new combination studies in 2018,” Hoos added.
Common blood cancer
Altough not a common cancer, in the United States multiple myeloma is the second most common blood cancer – following non-Hodgkin lymphoma. The lifetime risk for multiple myeloma is about 1 in 143.
Based on estimates from the American Cancer Society, in 2017 a total of 30,280 adults (17,490 men and 12,790 women) in the United States will be diagnosed with multiple myeloma and 12,590 will die from the disease (6,660 men and 5,930 women). The disease is generally considered treatable but not curable. Multiple myeloma commonly becomes refractory to available treatments, so research into new treatments is vital.
Results from the dose escalation phase of the study were presented earlier, during the 2016 annual meeting of the American Society of Hematology. 
* A total of 18 patients discontinued treatment for disease progression (n=15), Adverse Events (n=2; thrombocytopenia, CPK elevation), or patient decision (n=1). Seventeen (17) patiens are ongoing.
Last Editorial Review: December 12, 2017
Featured Image: 59th American Society of hematology (ASH) Annual Meeting and Exposition, General views. Courtesy: © 2017. American Society of Hematology. Used with permission.
Copyright © 2017 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.